CG Oncology (CGON) Competitors $20.11 +0.05 (+0.25%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$18.74 -1.38 (-6.84%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGON vs. BPMC, SRPT, TLX, AXSM, KRYS, NUVL, GRFS, ELAN, VRNA, and ADMAShould you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. CG Oncology vs. Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Krystal Biotech Nuvalent Grifols Elanco Animal Health Verona Pharma ADMA Biologics CG Oncology (NASDAQ:CGON) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership. Do institutionals and insiders believe in CGON or BPMC? 26.6% of CG Oncology shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer CGON or BPMC? CG Oncology currently has a consensus target price of $63.88, suggesting a potential upside of 217.63%. Blueprint Medicines has a consensus target price of $124.95, suggesting a potential upside of 53.41%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.70 Is CGON or BPMC more profitable? Blueprint Medicines has a net margin of -13.19% compared to CG Oncology's net margin of -10,642.98%. CG Oncology's return on equity of -18.97% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Blueprint Medicines -13.19%-77.49%-20.84% Does the media refer more to CGON or BPMC? In the previous week, Blueprint Medicines had 3 more articles in the media than CG Oncology. MarketBeat recorded 10 mentions for Blueprint Medicines and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.15 beat Blueprint Medicines' score of 1.03 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Blueprint Medicines 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, CGON or BPMC? CG Oncology has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Does the MarketBeat Community believe in CGON or BPMC? Blueprint Medicines received 526 more outperform votes than CG Oncology when rated by MarketBeat users. However, 92.31% of users gave CG Oncology an outperform vote while only 68.15% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes2492.31% Underperform Votes27.69%Blueprint MedicinesOutperform Votes55068.15% Underperform Votes25731.85% Which has stronger valuation and earnings, CGON or BPMC? CG Oncology has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$1.14M1,345.68-$48.61M-$1.42-14.16Blueprint Medicines$508.82M10.23-$67.09M-$1.08-75.42 SummaryCG Oncology beats Blueprint Medicines on 11 of the 18 factors compared between the two stocks. Remove Ads Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGON vs. The Competition Export to ExcelMetricCG OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-14.1631.0021.7317.81Price / Sales1,345.68441.15379.1994.60Price / CashN/A168.6838.1534.64Price / Book-10.373.476.464.00Net Income-$48.61M-$72.06M$3.20B$247.23M7 Day Performance28.99%9.33%6.54%7.26%1 Month Performance-27.66%-16.97%-8.55%-6.26%1 Year Performance-46.57%-29.10%10.33%-0.18% CG Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGONCG Oncology1.2512 of 5 stars$20.11+0.2%$63.88+217.6%-46.6%$1.53B$1.14M-14.1661Positive NewsBPMCBlueprint Medicines2.6336 of 5 stars$80.20-1.8%$124.95+55.8%-4.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6781 of 5 stars$52.40-3.7%$163.18+211.4%-54.0%$5.08B$1.90B41.92840Short Interest ↑Gap DownHigh Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5817 of 5 stars$98.50-0.4%$169.80+72.4%+52.2%$4.80B$385.69M-16.44380Analyst RevisionKRYSKrystal Biotech4.6473 of 5 stars$166.01-3.1%$220.00+32.5%-0.4%$4.78B$290.52M55.52210NUVLNuvalent1.8517 of 5 stars$64.68-1.6%$113.44+75.4%+8.4%$4.63BN/A-18.6440Positive NewsGRFSGrifols3.0933 of 5 stars$6.55-1.5%N/A+6.9%$4.50B$7.21B5.6026,300Gap UpELANElanco Animal Health4.3455 of 5 stars$8.95-2.2%$15.17+69.6%-40.6%$4.44B$4.44B22.369,800Analyst ForecastGap DownVRNAVerona Pharma2.2461 of 5 stars$54.30+0.7%$69.14+27.3%+270.1%$4.39B$42.28M-28.2830Positive NewsGap UpHigh Trading VolumeADMAADMA Biologics1.8913 of 5 stars$18.40+2.2%$22.50+22.3%+270.4%$4.35B$426.45M65.71530Options VolumeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Blueprint Medicines Competitors Sarepta Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Axsome Therapeutics Competitors Krystal Biotech Competitors Nuvalent Competitors Grifols Competitors Elanco Animal Health Competitors Verona Pharma Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGON) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
